BRPI0410975A - forma cristalina de prolina racemase de trypanosoma cruzi praca (tcpraca), composição, métodos para fabricar uma forma cristalina de tcpraca e para identificar uma substáncia que pode ligar-se à tcpraca e consequentemente afetar a atividade biológica de tcpraca, substáncia, dispositivo para realizar o método, método para projetar uma molécula que afeta a atividade biológica de tcpraca, e, molécula - Google Patents

forma cristalina de prolina racemase de trypanosoma cruzi praca (tcpraca), composição, métodos para fabricar uma forma cristalina de tcpraca e para identificar uma substáncia que pode ligar-se à tcpraca e consequentemente afetar a atividade biológica de tcpraca, substáncia, dispositivo para realizar o método, método para projetar uma molécula que afeta a atividade biológica de tcpraca, e, molécula

Info

Publication number
BRPI0410975A
BRPI0410975A BRPI0410975-9A BRPI0410975A BRPI0410975A BR PI0410975 A BRPI0410975 A BR PI0410975A BR PI0410975 A BRPI0410975 A BR PI0410975A BR PI0410975 A BRPI0410975 A BR PI0410975A
Authority
BR
Brazil
Prior art keywords
prostate
molecule
substance
biological activity
crystalline form
Prior art date
Application number
BRPI0410975-9A
Other languages
English (en)
Inventor
Paola Minoprio
Pedro Alzari
Alejandro Buschiazzo
Wim Degrave
Christophe Gregoire
Nathalie Chamond
Armand Berneman
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of BRPI0410975A publication Critical patent/BRPI0410975A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Seasonings (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"FORMA CRISTALINA DE PROLINA RACEMASE DE TRYPANOSOMA CRUZI PRACA (TCPRACA), COMPOSIçãO, MéTODOS PARA FABRICAR UMA FORMA CRISTALINA DE TCPRACA E PARA IDENTIFICAR UMA SUBSTáNCIA QUE PODE LIGAR-SE à TCPRACA E CONSEQUENTEMENTE AFETAR A ATIVIDADE BIOLóGICA DE TCPRACA, SUBSTáNCIA, DISPOSITIVO PARA REALIZAR O MéTODO, MéTODO PARA PROJETAR UMA MOLéCULA QUE AFETA A ATIVIDADE BIOLóGICA DE TCPRACA, E, MOLéCULA". A presente invenção fornece a estrutura cristalina da Trypanosoma cruzi PRACA prolina racemase. Métodos para modelar medicamentos que tratam ou previnem a infecção pelo T. cruzi também são fornecidos , como o são os medicamentos que são identificados.
BRPI0410975-9A 2003-05-30 2004-06-01 forma cristalina de prolina racemase de trypanosoma cruzi praca (tcpraca), composição, métodos para fabricar uma forma cristalina de tcpraca e para identificar uma substáncia que pode ligar-se à tcpraca e consequentemente afetar a atividade biológica de tcpraca, substáncia, dispositivo para realizar o método, método para projetar uma molécula que afeta a atividade biológica de tcpraca, e, molécula BRPI0410975A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47423803P 2003-05-30 2003-05-30
US48466103P 2003-07-07 2003-07-07
PCT/IB2004/002062 WO2004106506A2 (en) 2003-05-30 2004-06-01 Crystallographic structure of trypanosoma cruzi proline racemase (tcpraca) and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0410975A true BRPI0410975A (pt) 2006-07-04

Family

ID=33493377

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410975-9A BRPI0410975A (pt) 2003-05-30 2004-06-01 forma cristalina de prolina racemase de trypanosoma cruzi praca (tcpraca), composição, métodos para fabricar uma forma cristalina de tcpraca e para identificar uma substáncia que pode ligar-se à tcpraca e consequentemente afetar a atividade biológica de tcpraca, substáncia, dispositivo para realizar o método, método para projetar uma molécula que afeta a atividade biológica de tcpraca, e, molécula

Country Status (6)

Country Link
US (1) US8099245B2 (pt)
EP (1) EP1629092B1 (pt)
AT (1) ATE490269T1 (pt)
BR (1) BRPI0410975A (pt)
DE (1) DE602004030330D1 (pt)
WO (1) WO2004106506A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114854728B (zh) * 2022-05-12 2023-11-24 云南师范大学 一种脯氨酸消旋酶及其制备和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7556939B2 (en) 2003-02-11 2009-07-07 Institut Pasteur Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase
US7585656B2 (en) 2003-02-11 2009-09-08 Institute Pasteur Crystallographic structure of TcPRACA and uses therefor
US8099245B2 (en) 2003-05-30 2012-01-17 Institut Pasteur Crystallographic structure of Trypanosoma cruzi proline racemase and uses therefor
EP2272510A1 (en) * 2009-07-06 2011-01-12 Institut Pasteur Inhibitors of the proline racemase of trypanosoma cruzi
ES2905625T3 (es) * 2012-09-28 2022-04-11 Nunhems Bv Plantas de Solanum lycopersicum con alteraciones no transgénicas en el gen acs4
CN113087319A (zh) * 2021-05-21 2021-07-09 北京赛科康仑环保科技有限公司 一种处理稀土或有色冶炼高盐高cod废水的系统及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5581595A (en) 1978-12-14 1980-06-19 Matsushita Electric Ind Co Ltd Method of analyzing aminoacid
US5856116A (en) * 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
WO2000009744A1 (en) 1998-08-13 2000-02-24 American Home Products Corporation Crystal structure of escherichia coli gdp-fucose synthetase and methods of its use
US6524589B1 (en) 1999-04-08 2003-02-25 Schering Corporation Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
US6713617B2 (en) 1999-12-03 2004-03-30 Institut Pasteur Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens
US6546074B1 (en) 2001-03-27 2003-04-08 Astex Technology Limited Protein crystal structure and method for identifying protein modulators
US7556939B2 (en) * 2003-02-11 2009-07-07 Institut Pasteur Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase
US7585656B2 (en) 2003-02-11 2009-09-08 Institute Pasteur Crystallographic structure of TcPRACA and uses therefor
US8099245B2 (en) 2003-05-30 2012-01-17 Institut Pasteur Crystallographic structure of Trypanosoma cruzi proline racemase and uses therefor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114854728B (zh) * 2022-05-12 2023-11-24 云南师范大学 一种脯氨酸消旋酶及其制备和应用

Also Published As

Publication number Publication date
US20080113422A1 (en) 2008-05-15
EP1629092B1 (en) 2010-12-01
WO2004106506A2 (en) 2004-12-09
DE602004030330D1 (de) 2011-01-13
ATE490269T1 (de) 2010-12-15
WO2004106506A3 (en) 2007-06-07
EP1629092A2 (en) 2006-03-01
US8099245B2 (en) 2012-01-17

Similar Documents

Publication Publication Date Title
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA200802213A1 (ru) Способы лечения заболеваний крови
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
EA200900959A1 (ru) Ингибиторы мек
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
UA96565C2 (ru) Пиридильные ингибиторы хеджхоговской передачи сигнала
EA200870391A1 (ru) Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека
MA29595B1 (fr) Anticorps anti-cd40 humanises et procedes d'utilisation
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
BRPI0607306A2 (pt) derivados de quinoxalina como agentes anti-tumor
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
ATE461923T1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
EA201000886A1 (ru) Органические соединения
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CY1113309T1 (el) Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200900767A1 (ru) Антагонистические антитела против ephb3
ATE345340T1 (de) N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 9/00

Ipc: C12N 9/90 (2006.01), A61K 39/005 (2006.01), A61P 3

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.